SMART MONEY GROUP

[Covid19freak]

LIFE =trading UNDER Cash/ Covid 19 Phase 2 results anyday now =Potential 10 Bagger UPSIDE GEM....Undiscovered stock

Market Cap $34 million / Cash $42 million / Shares Out 10 Million


"The Phase 2 trial of ATYR1923 in COVID-19 patients with severe respiratory complications is progressing right on track, with a topline readout set to come by YE20.

Part of what makes the therapy stand out is its unique mechanism of action, which makes it well suited for use in treating severe respiratory complications, in Singh’s opinion. Importantly, based on the therapy’s preclinical model in ARDS, the analyst argues LIFE could potentially establish PoC efficacy data in COVID-19 prior to PS.

This prompted Singh to comment, “We believe ATYR1923's ‘blue sky scenario’ in COVID-19 patients looks promising, given the lack of novel targeted therapies for severe respiratory complications by SARS-CoV-2 and other triggers... We see a likelihood that, under such a rigorous trial design, positive data could potentially get ATYR1923 an emergency use authorization without having to expand into a full Phase 3.”

If that wasn’t enough, Singh thinks LIFE’s NRP2 science has “significant opportunities beyond the current pipeline. This could be expanded into additional inflammatory/fibrotic lung diseases and cancers in 2021.”

Expounding on this, Singh said, “Expected by YE20 is an IND monoclonal antibody aTyr will declare from its Neuropilin-2 (NRP2) antibody program. Multiple NRP2 antibodies demonstrated anti-tumor effects; one of them (aNRP2-10) blocked VEGF-C binding to NRP2, exhibiting increased sensitivity to chemotherapy in preclinical models of triple-negative breast cancer (TNBC).”

Based on all of the above, Singh rates LIFE an Outperform (i.e. Buy) along with an $12 price target. "

https://finance.yahoo.com/news/oppenheimer-3-penny-stocks-triple-193042532.html